RA CAPITAL MANAGEMENT, L.P. bought ACRV

May 18, 2026 · Form 4 insider transaction

RA CAPITAL MANAGEMENT, L.P. bought 9,366 shares of Acrivon Therapeutics, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 2 days after the transaction.

Direction
Acquired (buy-side)
Shares
9,366
Price
$0.00
Total value
N/A
RoleDirector, 10% owner
SecurityCommon Stock
Transaction codeA: Grant or award
Transaction dateMay 18, 2026
Filing dateMay 20, 2026
Shares owned after9,366
OwnershipIndirect
10b5-1 planNo
AmendedNo

Footnotes

Represents the grant of a restricted stock unit ("RSU") award to Derek DiRocco. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on March 18, 2027, subject to Dr. DiRocco's continuous service as a director through such vesting date.; Under Dr. DiRocco's arrangement with the Adviser, Dr. DiRocco holds the RSUs for the benefit of the Fund and the Nexus Fund II. Dr. DiRocco is obligated to turn over to the Adviser any stock received upon settlement of the RSUs, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the RSUs and underlying common stock.; RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund II, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.

View the original Form 4 on SEC EDGAR